2023
Dysregulation of the endogenous cannabinoid system following opioid exposure
Mohammad Aghaei A, Saali A, Canas M, Weleff J, D'Souza D, Angarita G, Bassir Nia A. Dysregulation of the endogenous cannabinoid system following opioid exposure. Psychiatry Research 2023, 330: 115586. PMID: 37931479, PMCID: PMC10842415, DOI: 10.1016/j.psychres.2023.115586.Peer-Reviewed Original ResearchConceptsEndocannabinoid systemECS componentsBrain regionsNovel neurobiological targetsTreatment of OUDEndogenous opioid systemOpioid-related deathsEndogenous cannabinoid systemSpecific brain regionsECS dysregulationOpioid exposureOUD treatmentOpioid systemCannabinoid systemNeurobiological targetsNew medicationsPreclinical literatureCannabinoid receptorsEndogenous ligandTherapeutic potentialStudy typePresent potential targetsExposure protocolOpioidsPreclinical research
2018
The Psychiatric Consequences of Cannabinoids
De Aquino JP, Sherif M, Radhakrishnan R, Cahill JD, Ranganathan M, D'Souza D. The Psychiatric Consequences of Cannabinoids. Clinical Therapeutics 2018, 40: 1448-1456. PMID: 29678279, DOI: 10.1016/j.clinthera.2018.03.013.Peer-Reviewed Original ResearchConceptsPsychiatric effectsPsychiatric disordersPre-existing psychiatric disordersCannabis useLong-term brain changesRates of cannabisNegative psychiatric outcomesNegative psychiatric effectsDose-dependent effectPublic mental healthCannabinoid exposureWithdrawal syndromeCannabis exposureAcute effectsBrain changesMood disordersPsychiatric outcomesGeneral populationPsychomotor functionHealthy individualsMedical cannabisPsychiatric consequencesChronic exposureSignificant impairmentMental health
2016
Human Laboratory Studies on Cannabinoids and Psychosis
Sherif M, Radhakrishnan R, D’Souza D, Ranganathan M. Human Laboratory Studies on Cannabinoids and Psychosis. Biological Psychiatry 2016, 79: 526-538. PMID: 26970363, DOI: 10.1016/j.biopsych.2016.01.011.BooksConceptsCannabinoid agonistsPsychotomimetic effectsAcute psychotomimetic effectsHealthy control subjectsCrossover laboratory studyEffects of ketamineHuman laboratory studiesGamma-aminobutyric acidHealthy human subjectsSelf-medication hypothesisTransient exacerbationAntipsychotic medicationControl subjectsDopamine metabolismGlutamate systemDopamine releasePsychotomimetic drugsCognitive symptomsDrug AdministrationAgonistsMagnitude of effectSymptomsSchizophreniaCannabinoidsLaboratory studies
2001
Cannabinoid Antagonists: A Treatment in Search of an Illness
D'Souza D, Kosten T. Cannabinoid Antagonists: A Treatment in Search of an Illness. JAMA Psychiatry 2001, 58: 330-331. PMID: 11296092, DOI: 10.1001/archpsyc.58.4.330.Peer-Reviewed Original Research